Related Experiment Videos
[The treatment of heart insufficiency in coronary heart disease]
Insights
Congestive heart failure in ischemic heart disease signals a poor prognosis. Effective treatment involves revascularization for cardiogenic shock and tailored drug therapies, including ACE-inhibitors and digitalis, for chronic conditions to improve patient outcomes.
Area of Science:
- Cardiology
- Internal Medicine
Context:
- Congestive heart failure (CHF) in ischemic heart disease (IHD) is associated with poor prognosis.
- Acute myocardial infarction (AMI) management requires specific therapeutic strategies based on patient subsets.
Purpose:
- To outline treatment strategies for congestive heart failure in both acute and chronic ischemic heart disease.
- To differentiate management approaches for cardiogenic shock versus other forms of CHF in IHD.
Summary:
- Acute revascularization via percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass grafting (CABG) significantly improves outcomes in cardiogenic shock due to extensive ischemic damage.
- Pharmacological management for CHF in IHD includes nitrates for pre- and afterload reduction, inotropes (dopamine or dobutamine) based on blood pressure, and amrinone as an alternative.
- For chronic IHD with CHF, complete revascularization is indicated when feasible. Drug therapy aims to halt disease progression and relieve symptoms, often involving early combination of ACE-inhibitors with diuretics, and digitalis for refractory cases.
Impact:
- This approach optimizes treatment selection for patients with ischemic heart disease and congestive heart failure.
- Improved management strategies can lead to better clinical outcomes and prognosis for affected individuals.
Abstract:
In acute as well as in chronic ischemic heart disease, congestive heart failure indicates a poor prognosis. Treatment after acute myocardial infarction should differentiate between specific subsets. In cardiogenic shock due to extensive ischemic damage, acute revascularization by PTCA or CABG improves the otherwise poor outcome substantially. In congestive heart failure, pre- and afterload reduction by nitrates should be combined with dopamine if systolic blood pressure is below 100 mmHG or dobutamine if an inotropic substance is necessary despite systolic blood pressure greater than 100 mmHg. Amrinone is a potent alternative which combines positive inotropic and vasodilating properties. In chronic ischemic heart disease, congestive heart failure is a clearly defined indication for complete revascularization, if possible. As to drug treatment, progression of the disease characterized by a cardiomyopathy of overload as well as neurohormonal and peripheral maladaptation should be stopped in parallel with symptom relief. Therefore, ACE-Inhibitors are combined very early with diuretic treatment, and digitalis should be added in refractory patients.